title: Predominant activation of endothelin-dependent cardiac hypertrophy by norepinephrine in rat left ventricle.
abstract: Locally released endothelin (ET)-1 has been recently identified as an important mediator of cardiac hypertrophy. It is still unclear, however, which primary stimulus specifically activates ET-dependent signaling pathways. We therefore examined in adult rats (n = 51) the effects of a selective ET(A) receptor antagonist in experimental models of cardiac hypertrophy, in which myocardial growth is predominantly initiated by a single primary stimulus. Rats were exposed to mechanical overload (ascending aortic stenosis), increased levels of circulating ANG II (ANG II infusion combined with hydralazine), or adrenergic stimulation (infusion of norepinephrine in a subpressor dose) for 7 days. All experimental treatments significantly increased left ventricular weight/body weight ratios compared with untreated rats, whereas systolic left ventricular peak pressure was increased only after ascending aortic stenosis. ET(A) receptor blockade exclusively reduced norepinephrine-induced cardiac hypertrophy and atrial natriuretic peptide gene expression. Blood pressure levels and heart rates remained unaffected during ET(A) receptor blockade in all experimental groups. These data indicate that in rat left ventricle, the ET-dependent signaling pathway leading to early development of cardiac hypertrophy and fetal gene expression is primarily activated by norepinephrine.
authors.affiliation: Institut für Physiologie und Pathophysiologie, Ruprecht-Karls Universität, 69120 Heidelberg, Germany.
authors.forename: Lutz
authors.initials: L
authors.lastname: Moser
authors.forename: Jörg
authors.initials: J
authors.lastname: Faulhaber
authors.forename: Rudolf J
authors.initials: RJ
authors.lastname: Wiesner
authors.forename: Heimo
authors.initials: H
authors.lastname: Ehmke
mesh_terms: D000804:Angiotensin II; D000818:Animals; D000959:Antihypertensive Agents; D001011:Aorta; D001024:Aortic Valve Stenosis / Q000150:complications; D009320:Atrial Natriuretic Factor / Q000235:genetics; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000502:physiology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006830:Hydralazine; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced* / Q000209:etiology*; D009638:Norepinephrine / Q000494:pharmacology; D010666:Phenylpropionates / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D010666:Phenylpropionates; D011743:Pyrimidines; D044022:Receptor, Endothelin A; D000804:Angiotensin II; D006830:Hydralazine; C107831:darusentan; D009320:Atrial Natriuretic Factor; D009638:Norepinephrine